AQR Capital Management LLC Sells 2,941 Shares of Simulations Plus, Inc. (NASDAQ:SLP)

AQR Capital Management LLC cut its stake in shares of Simulations Plus, Inc. (NASDAQ:SLP) by 25.8% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 8,455 shares of the technology company’s stock after selling 2,941 shares during the quarter. AQR Capital Management LLC’s holdings in Simulations Plus were worth $411,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also added to or reduced their stakes in the stock. Silvercrest Asset Management Group LLC acquired a new position in shares of Simulations Plus in the first quarter worth approximately $4,717,000. Wasatch Advisors LP boosted its stake in shares of Simulations Plus by 36.5% in the 1st quarter. Wasatch Advisors LP now owns 381,693 shares of the technology company’s stock valued at $15,707,000 after purchasing an additional 102,135 shares during the last quarter. Congress Asset Management Co. MA increased its position in shares of Simulations Plus by 34.6% during the first quarter. Congress Asset Management Co. MA now owns 171,490 shares of the technology company’s stock worth $7,057,000 after buying an additional 44,129 shares during the period. Dimensional Fund Advisors LP raised its stake in Simulations Plus by 10.1% during the second quarter. Dimensional Fund Advisors LP now owns 414,005 shares of the technology company’s stock worth $20,128,000 after buying an additional 37,992 shares during the last quarter. Finally, SG Americas Securities LLC acquired a new position in Simulations Plus in the second quarter valued at $1,320,000. 78.08% of the stock is currently owned by institutional investors and hedge funds.

Simulations Plus Price Performance

NASDAQ SLP opened at $31.50 on Wednesday. The company’s 50 day simple moving average is $33.65 and its two-hundred day simple moving average is $41.18. The stock has a market capitalization of $630.25 million, a PE ratio of 65.63 and a beta of 0.69. Simulations Plus, Inc. has a 1 year low of $29.37 and a 1 year high of $51.22.

Analysts Set New Price Targets

SLP has been the topic of several research analyst reports. Craig Hallum restated a “buy” rating and set a $56.00 target price on shares of Simulations Plus in a research report on Wednesday, July 3rd. JMP Securities began coverage on shares of Simulations Plus in a research note on Tuesday, July 16th. They issued a “market perform” rating for the company. William Blair reissued an “outperform” rating on shares of Simulations Plus in a research note on Thursday, September 12th. Finally, KeyCorp assumed coverage on shares of Simulations Plus in a research note on Monday, July 29th. They issued an “overweight” rating and a $47.00 price target for the company. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat.com, Simulations Plus has an average rating of “Moderate Buy” and an average price target of $56.00.

Insider Transactions at Simulations Plus

In other news, Director Walter S. Woltosz sold 20,000 shares of the company’s stock in a transaction on Tuesday, September 3rd. The shares were sold at an average price of $35.18, for a total value of $703,600.00. Following the completion of the sale, the director now owns 3,501,592 shares of the company’s stock, valued at approximately $123,186,006.56. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In the last three months, insiders sold 60,750 shares of company stock worth $2,145,055. 20.90% of the stock is currently owned by corporate insiders.

Simulations Plus Profile

Simulations Plus, Inc develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products.